Xeris Biopharma (XERS) Q2 2026: Recorlev Soars 81%, Secures Durable Growth Platform

2026-08-06 | By EarningsIQ Research

Recorlev’s breakout performance and a newly fortified IP moat propelled Xeris to a record quarter, while disciplined capital moves eliminated debt overhang and set the stage for pipeline acceleration. With the commercial team expansion now yielding early returns and XP-8121 poised for a pivotal phase, Xeris is building a defensible, high-growth biopharma platform with multi-year visibility.

Summary

• Recorlev’s Dominance Expands: Commercial execution and prescriber adoption are rapidly widening Xeris’ lead in Cushing’s syndrome care.
• Balance Sheet Transformation: Full retirement of convertible notes removes interest drag and clarifies capital structure.
• Pipeline Inflection Approaches: XP-8121 advances toward Phase III, with IP wins and clinical momentum supporting long-term optionality.

Business Overview

Xeris Biopharma is a specialty pharmaceutical company focused on endocrine and rare disease therapies. It generates revenue through three primary commercial products: Recorlev, a cortisol synthesis inhibitor for endogenous Cushing’s syndrome; Gvoke, a ready-to-use glucagon for severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis (PPP). Xeris also invests in pipeline innovation, notably XP-8121 for hypothyroidism, leveraging proprietary formulation technology and a growing intellectual property estate.

Performance Analysis

Xeris delivered total revenue of $92 million in Q2, with net product revenue up 34% year-over-year, powered by an 81% surge in Recorlev sales. Recorlev’s momentum was supported by record levels of referrals, new patient starts, and prescriber breadth, reflecting both commercial team expansion and deepening physician confidence. Gvoke rebounded after a slow Q1, with sequential prescription growth of 10% and expectations for seasonal lift in Q3. Keveyis maintained its resilient trajectory, buoyed by a new patent allowance that extends protection through at least 2039.

Gross margin improved to 86%, up nearly 400 basis points, driven by favorable product mix. Operating expenses increased as Xeris invested in commercial expansion and pipeline advancement, particularly for XP-8121, but adjusted EBITDA grew over 50% year-over-year to $19.3 million. The full retirement of $34 million in convertible notes, completed post-quarter, eliminates $3 million in annual interest expense and removes a balance sheet overhang.

• Recorlev’s Growth Engine: 81% YoY sales growth, with new and existing prescribers expanding in line with expectations.
• Gvoke’s Sequential Recovery: Prescription growth and normalization after early-year softness, with third-quarter seasonality expected to drive further gains.
• Keveyis IP Win: New patent extends exclusivity, enabling renewed investment in patient identification and support.

Commercial momentum is translating into financial strength and operational flexibility, even as the company ramps up investment in its late-stage pipeline.

Executive Commentary

Strategic Positioning

1. Recorlev Commercial Expansion

The January expansion of the Recorlev sales force is now delivering measurable impact, with new prescriber and patient metrics tracking in line with internal models. Management emphasized that the majority of expansion benefits are still to come in the back half, supported by robust leading indicators such as referrals and new patient starts. This suggests both breadth and depth of market penetration are increasing, with over 60% of patients new to therapy, pointing to genuine category growth rather than share shift.

2. Intellectual Property Fortification

Xeris secured a new patent for Keveyis, extending exclusivity through 2039, and expanded IP coverage for XP-8121 with two additional U.S. patents. This IP strategy not only raises barriers to entry for competitors but also justifies incremental investment in both mature and pipeline assets, ensuring durable cash flow from established brands while de-risking future launches.

3. Pipeline Advancement and Optionality

XP-8121, a long-acting levothyroxine for hypothyroidism, is on track for Phase III initiation by year-end. Management is focused on ensuring a commercial-ready product before starting the trial, aligning R&D and go-to-market execution. The September 9th webinar will provide detailed guidance on clinical and regulatory timelines, with management reiterating their 2030 launch target and highlighting the multi-billion dollar market opportunity.

4. Capital Structure Optimization

With the full retirement of convertible notes, Xeris eliminated $34 million in debt and $3 million in annual interest expense. This move enhances strategic flexibility and signals confidence in the company’s cash generation and growth trajectory.

5. Disciplined Resource Allocation

SG&A is now expected to increase $50 million year-over-year, reflecting further commercial investment. R&D spend is guided to rise $25 million, almost entirely for XP-8121, with management signaling a willingness to invest behind high-conviction opportunities while maintaining EBITDA growth.

Key Considerations

Xeris’ Q2 results showcase a business balancing rapid commercial expansion, pipeline investment, and capital discipline. Investors should weigh the sustainability of Recorlev’s trajectory, the durability of IP protection, and the execution risks around XP-8121’s pivotal phase.

Key Considerations:

• Recorlev’s Market Penetration: Over 60% of new patients are first-time therapy users, suggesting untapped market expansion rather than simple share gains.
• Gvoke’s Rebound and Seasonality: Q2 recovery sets up for a typical Q3 back-to-school demand spike, but long-term penetration remains a challenge.
• Keveyis Durability Post-Patent: New IP protection supports continued investment in patient identification, even in a non-exclusive environment.
• Pipeline Execution Risk: XP-8121’s Phase III initiation is contingent on commercial readiness, demanding tight cross-functional coordination.
• OpEx Scaling: Incremental SG&A and R&D investments are necessary to sustain growth, but require vigilant productivity tracking to avoid margin dilution.

Risks

Xeris faces execution risk as it scales commercial teams and initiates a pivotal XP-8121 trial, with any delays or missteps potentially impacting growth and valuation. The competitive landscape for both Cushing’s syndrome and hypothyroidism therapies remains dynamic, and while new IP protection is a positive, generic threats and payer dynamics are persistent concerns. Increased SG&A and R&D outlays could pressure profitability if top-line momentum slows. Management’s guidance implies continued outperformance, but any disruption in prescriber adoption, patient retention, or pipeline progress could alter the company’s trajectory.

Forward Outlook

For Q3 and the second half of 2026, Xeris guided to:

• Full-year total revenue of $385 to $390 million, reflecting at least 33% YoY growth at the midpoint
• Gross margin improvement and continued adjusted EBITDA expansion, even with increased SG&A and R&D investment

Management highlighted several factors that will drive performance:

• Further yield from Recorlev sales force expansion, with leading indicators such as new prescribers and referrals supporting confidence in H2 acceleration
• Gvoke’s seasonal lift expected in Q3, with longer-term growth tied to closing the penetration gap in diabetes care

Takeaways

• Commercial Flywheel Accelerates: Recorlev’s 81% growth and expanding prescriber base confirm Xeris’ ability to compound commercial momentum with targeted investment.
• IP and Balance Sheet Strength: New patent wins and the elimination of convertible debt both reduce risk and increase the company’s optionality for pipeline and M&A moves.
• Pipeline Execution is the Next Catalyst: Investors should monitor XP-8121’s Phase III readiness and the September 9th update for clarity on development timelines and commercial strategy.

Conclusion

Xeris Biopharma delivered a record Q2, leveraging Recorlev’s breakout performance and a fortified IP position to drive both near-term growth and long-term defensibility. With a clean balance sheet and a pivotal pipeline program on the horizon, Xeris is positioned as a high-growth, specialty pharma platform with multiple levers for value creation.

Industry Read-Through

Xeris’ results reinforce the value of targeted commercial expansion and IP-driven differentiation in specialty pharma. The success of Recorlev’s sales force expansion and the rapid translation of new prescriber activity into revenue offer a playbook for other rare disease and endocrine-focused companies. The Keveyis patent win highlights the importance of lifecycle management in ultra-rare markets, especially as generic threats persist. Finally, Xeris’ willingness to invest ahead of the curve in both commercial and pipeline assets, while maintaining EBITDA growth, sets a benchmark for balancing risk and reward in the current biopharma environment. Investors in the sector should monitor how pipeline readiness and commercial execution converge as the next phase of growth unfolds.

XERS Healthcare Pharmaceuticals Commercialization Specialty Pharma Intellectual Property Pipeline Endocrinology